Tactile sensing device for documenting clinical breast exams
19 December 2005
California-based Medical Tactile, Inc. (MTI) has announced the start of
commercial sales of its first product, the SureTouch Visual Mapping System
for electronically documenting clinical breast exam results.
The system has been cleared for commercial sale by the U.S. Food and Drug
Administration as an adjunct device for performing and documenting clinical
Based on the company's proprietary tactile sensing technology, the
SureTouch System improves the sensitivity, specificity and objectivity of
manual breast palpation exams, which are the most accessible first line of
defence against breast cancer for most women.
To use the system, the healthcare practitioner simply palpates suspicious
breast lesions with the hand-held tactile probe, which employs highly
sensitive sensors clinically proven to map lesions as small as 5 mm. The
portable SureTouch console creates an electronic record that provides a
range of objective information to help recognize suspicious legions and make
informed recommendations for follow-up radiological diagnostics such as
mammography and ultrasound.
"We are very pleased to begin commercial sales of the first-of-its-kind
SureTouch System," said Steve Weiss, Medical Tactile's CEO. "We have worked
hard to develop an innovative, cost-effective technology that enables
healthcare practitioners to improve early breast cancer diagnostics and save